Heterologous surface display on lactic acid bacteria: Non-GMO alternative?

Bioengineered

Volumn 6, Issue 3, 2015, Pages 179-183

  Zadravec, Petra ^a,b   Štrukelj, Borut ^a,b   Berlec, Aleš ^a  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bacteria like particles; Cell wall binding domains; EFSA; EMA; Genetically modified organism; Gram positive enhancer matrix; LysM; Regulatory agency; Surface display

Indexed keywords

ARTICLE; CELL SURFACE DISPLAY; FOOD AND DRUG ADMINISTRATION; LACTIC ACID BACTERIUM; LACTOBACILLUS FERMENTUM; LACTOBACILLUS SALIVARIUS; NONHUMAN; TRANSGENIC ORGANISM; CELL WALL; CHEMISTRY; CLASSIFICATION; LACTOBACILLUS; PROCEDURES;

HYBRID PROTEIN;

CELL SURFACE DISPLAY TECHNIQUES; CELL WALL; LACTOBACILLUS; ORGANISMS, GENETICALLY MODIFIED; RECOMBINANT FUSION PROTEINS;

EID: 84946827715     PISSN: 21655979     EISSN: 21655987     Source Type: Journal    
DOI: 10.1080/21655979.2015.1040956     Document Type: Article

References (26)

1. Lee SY, Choi JH, Xu Z. Microbial cell-surface display. Trends Biotechnol 2003; 21:45-52; PMID:12480350; http://dx.doi.org/10.1016/S0167-7799(02)00006-9
2. Berlec A, Ravnikar M, Strukelj B. Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 2012; 67:891-8; PMID:23210237
3. Mesnage S, Dellarole M, Baxter NJ, Rouget JB, Dimitrov JD, Wang N, Fujimoto Y, Hounslow AM, Lacroix-Desmazes S, Fukase K, et al. Molecular basis for bacterial peptidoglycan recognition by LysM domains. Nat Commun 2014; 5:4269; PMID:24978025; http://dx.doi.org/ 10.1038/ncomms5269
4. Oliveira H, Melo LD, Santos SB, Nobrega FL, Ferreira EC, Cerca N, Azeredo J, Kluskens LD. Molecular aspects and comparative genomics of bacteriophage endolysins. J Virol 2013; 87:4558-70; PMID:23408602; http://dx.doi. org/10.1128/JVI.03277-12
5. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol 2012; 7:1147-71; PMID:23030422; http://dx.doi. org/10.2217/fmb.12.97
6. Steen A, Buist G, Leenhouts KJ, El Khattabi M, Grijpstra F, Zomer AL, Venema G, Kuipers OP, Kok J. Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J Biol Chem 2003; 278:23874- 81; PMID:12684515; http://dx.doi.org/10.1074/jbc. M211055200
7. Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, Heger A, Hetherington K, Holm L, Mistry J, et al. Pfam: the protein families database. Nucleic Acids Res 2014; 42:D222-30; PMID:24288371; http://dx.doi.org/10.1093/nar/ gkt1223
8. Visweswaran GR, Leenhouts K, van Roosmalen M, Kok J, Buist G. Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications. Appl Microbiol Biotechnol 2014; 98:4331-45; PMID:24652063
9. Steen A, Palumbo E, Deghorain M, Cocconcelli PS, Delcour J, Kuipers OP, Kok J, Buist G, Hols P. Autolysis of Lactococcus lactis is increased upon D-alanine depletion of peptidoglycan and lipoteichoic acids. J Bacteriol 2005; 187:114-24; PMID:15601695
10. Moeini H, Rahim RA, Omar AR, Shafee N, Yusoff K. Lactobacillus acidophilus as a live vehicle for oral immunization against chicken anemia virus. Appl Microbiol Biotechnol 2011; 90:77-88; PMID:21181148
11. Hu S, Kong J, Kong W, Guo T, Ji M. Characterization of a novel LysM domain from Lactobacillus fermentum bacteriophage endolysin and its use as an anchor to display heterologous proteins on the surfaces of lactic acid bacteria. Appl Environ Microbiol 2010; 76:2410-8; PMID:20173067
12. Xu W, Huang M, Zhang Y, Yi X, Dong W, Gao X, Jia C. Novel surface display system for heterogonous proteins on Lactobacillus plantarum. Lett Appl Microbiol 2011; 53:641-8; PMID:21967414
13. Hu S, Kong J, Sun Z, Han L, Kong W, Yang P. Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein. Microb Cell Fact 2011; 10:86; PMID:22035337; http://dx.doi.org/ 10.1186/1475-2859-10-86
14. Zadravec P, Strukelj B, Berlec A. Improvement of LysM-mediated surface display of Designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus species. Appl Environ Microbiol 2015; 81:2098-106; PMID:25576617
15. Schmelcher M, Shabarova T, Eugster MR, Eichenseher F, Tchang VS, Banz M, Loessner MJ. Rapid multiplex detection and differentiation of Listeria cells by use of fluorescent phage endolysin cell wall binding domains. Appl Environ Microbiol 2010; 76:5745-56; PMID:20622130; http://dx.doi.org/10.1128/AEM. 00801-10
16. Gu J, Lu R, Liu X, Han W, Lei L, Gao Y, Zhao H, Li Y, Diao Y. LysGH15B, the SH3b domain of staphylococcal phage endolysin LysGH15, retains high affinity to staphylococci. Curr Microbiol 2011; 63:538-42; PMID:21947237; http://dx.doi.org/10.1007/s00284- 011-0018-y
17. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, Buist G, Kok J, Kuipers OP, Robillard G, et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol 2006; 72:880-9; PMID:16391130; http://dx.doi.org/10.1128/AEM.72. 1.880-889.2006
18. Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front Immunol 2013; 4:282; PMID:24062748
19. Kobierecka P, Wyszynska A, Maruszewska M, Wojtania A, Zylinska J, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria as a surface display platform for Campylobacter jejuni antigens. J Mol Microbiol Biotechnol 2015; 25:1-10; PMID:25662187
20. EFSA panel on genetically modified organisms. Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. EFSA Journal 2011; 9:2193-247
21. Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed. Official Journal of the European Union 2003; L 268:1-23.
22. Anliker B, Longhurst S, Buchholz CJ. Environmental risk assessment for medicinal products containing genetically modified organisms. Bundesgesundheitsbl 2010; 53:52-7; PMID:19940966; http://dx.doi.org/ 10.1007/s00103-009-0986-2
23. Regulation (EC) No 1394/2007 of the European parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 2007; L 324:121-37.
24. Committee for Advanced Therapies. Summaries of scientific recommendations on classification of advancedtherapy medicinal products. [Internet]. London: European Medicines Agency; [updated 2014 Oct 29; cited 2015 Mar 15]. Available from: http://www.ema. europa.eu/ema/index.jsp?curlDpages/regulation/gen eral/general_content_000301.jsp.
25. Committee for medicinal products for human use. Environmental risk assessments for medicinal products containing, or consisting of, genetically modified organisms (GMOs). [Internet]. Parma: European Food Safety Authority; 2006 Dec [cited 2015 Mar 15]. 14 p. Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2009/ 09/WC500003805.pdf
26. Guidance for clinical investigators, sponsors, and IRSs. Investigational new drug applications (INDs) - Determining whether human research studies can be conducted without an IND. [Internet]. Silver Spring: Food and Drug Administration; 2013 Sep [cited 2015 Mar 15]. 23 p. Available from: http://www.fda.gov/downloads/Drugs/Guidances/ UCM229175.pdf